SCHEMBL3325933

SCHEMBL3325933

CC1CCc2c(cc(-c3ccccc3)n2-c2ccc(C(=O)O)nc2)C1

nearest known ligand 0.60

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
MAPT P10636 18/20 0.60
TP53 P04637 11/20 0.60
THRB P10828 3/20 0.58
LMNA P02545 6/20 0.56
AHR P35869 1/20 0.41
SERPINE1 P05121 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3319136 0.84 MAPT (0.51) MAPTTP53THRBLMNA
SCHEMBL3323549 0.83 MAPT (0.75) MAPTTP53THRBLMNA
SCHEMBL3325860 0.81 MAPT (0.60) MAPTTP53THRBLMNAAHR
SCHEMBL3323176 0.80 MAPT (0.64) MAPTTP53THRBLMNAAHR
SCHEMBL3322493 0.80 MAPT (0.59) MAPTTP53THRBLMNAAHR
SCHEMBL3000767 0.79 TP53 (0.53) MAPTTP53THRBLMNAAHR
SCHEMBL3324506 0.77 MAPT (0.61) MAPTTP53THRBLMNA
SCHEMBL2997451 0.77 MAPT (0.63) MAPTTP53THRBLMNAAHR
SCHEMBL2993582 0.75 MAPT (0.56) MAPTTP53THRBLMNAAHR
SCHEMBL2981839 0.75 MAPT (0.61) MAPTTP53THRBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2139472-B1 TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2016-01-13 EP disclosed
US-8288432-B2 Tetrahydroindole derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2012-10-16 US disclosed
US-8288432-B2 Tetrahydroindole derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2012-10-16 US disclosed
US-8288432-B2 Tetrahydroindole derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2012-10-16 US disclosed
US-20100120749-A1 TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYO TEX SA (CH) 2010-05-13 US disclosed
US-20100120749-A1 TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYO TEX SA (CH) 2010-05-13 US disclosed
US-20100120749-A1 TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYO TEX SA (CH) 2010-05-13 US disclosed
EP-2139472-A1 TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYO TEX SA (CH) 2010-01-06 EP disclosed
WO-2008116926-A1 TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYO TEX SA (CH) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120749-A1 TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS CYBB, NQO1, NOX4 MAPT 1042/4885TP53 4124/4885THRB 1348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.